Immunotherapy Trial Gives Renewed Hope

After being diagnosed with metastatic prostate cancer that had spread to his bones, Rodney learned about a new study involving chimeric antigen receptor (CAR) T-cell therapy from his LCI care team.

CAR T-cell therapy is a personalized treatment that is made by removing T lymphocytes (also called T cells) from the patient and engineering them to be able to recognize and attack the patient’s own cancer cells.

Last year, Rodney became one of the first patients in the country and the first in the region to receive CAR T-cell therapy for prostate cancer. Since receiving his modified T cells, Rodney has not required any further therapy.

In 2022, Rodney Glover, pictured with his care team, became one of the first patients in the country and the first in the region to receive CAR T-cell therapy for prostate cancer.

Discover what Rodney's promising results could mean for other patients with metastatic disease. Read the full article at Atriumhealth.org/dailydose